Arena Pharmaceuticals (ARNA) 3.91 $ARNA
Contrave Sales Continue To Impress
Spencer Osborne - at Seeking Alpha - Fri Dec 12, 3:26PM CST
OREX: 5.74 (-0.02), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Arena: Belviq Sales See Pleasant Rebound
Spencer Osborne - at Seeking Alpha - Fri Dec 12, 3:05PM CST
OREX: 5.74 (-0.02), ARNA: 3.91 (-0.18)
Arena Pharmaceuticals (ARNA) Weak On High Volume Today
at The Street - Fri Dec 12, 9:01AM CST
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate
ARNA: 3.91 (-0.18)
Assessing The Beginnings Of The Orexigen Launch Of Contrave
Spencer Osborne - at Seeking Alpha - Wed Dec 10, 12:09PM CST
OREX: 5.74 (-0.02), ARNA: 3.91 (-0.18)
Belviq Still Lacking Coverage At The Top, But Could Recover In The Exchanges
Clinically Sound Investor - at Seeking Alpha - Tue Dec 09, 7:02AM CST
ARNA: 3.91 (-0.18)
Biotech Weekly: Everything You Want To Know About Small Cap Biotech Cult Stocks
Daniel Ward - at Seeking Alpha - Mon Dec 08, 10:35AM CST
HEB: 0.25 (-0.01), IBIO: 0.69 (unch), MNKD: 5.11 (-0.14), ARNA: 3.91 (-0.18)
Global Anti-Obesity Drugs Market 2015-2019: High Drug Development Costs & Stiff Market Competition
M2 - Mon Dec 08, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/pvmmtv/global) has announced the addition of the "Global Anti-Obesity Drugs Market 2015-2019" report to their offering. The Global Anti-obesity Drugs market to grow at a CAGR of 39.45 percent over the period 2014-2019 Obesity is a medical condition in which there is surplus accumulation of fat in the body. It is linked with increased illness risk, disability, and death. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure. Fierce competition among vendors to manufacture and market drugs that are both effective and safe is one of the major trends in the market. Competition in the market is expected to further intensify with the entry of new drugs in the market during the forecast period. The landscape is vast, with competitors ranging from Arena Pharmaceuticals and Orexigen Therapeutics to big pharmaceutical companies gearing up to make harmless anti-obesity drugs with lesser side effects. According to the report, an increase in the prevalence of obesity is one of the main drivers of the market. The prevalence of obesity is very high worldwide. An increase in the prevalence of obesity offers huge opportunities for drug manufacturing companies to develop and manufacture highly effective drugs. Further, the report states that the high cost of development of drugs is one of the primary challenges faced by the market. Regardless of the numerous benefits, the high cost involved with the development of anti-obesity drugs has direct impact on the pricing of the drug, thereby impeding the acceptability among patients. The Global Anti-obesity Drugs market can be divided into two segments: - Peripherally Acting Anti-obesity Drugs - Centrally Acting Anti-obesity Drugs Key Vendors - Arena Pharmaceuticals - F. Hoffmann-La Roche - GlaxoSmithKline - Orexigen Therapeutics - Vivus Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Types of Obesity - Causes of Obesity - Classification of Obesity - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/pvmmtv/global
OREX: 5.74 (-0.02), GSK: 42.42 (-0.93), ARNA: 3.91 (-0.18)
Arena's Belviq - Regulatory Update And A Recall
Spencer Osborne - at Seeking Alpha - Mon Dec 08, 8:01AM CST
ARNA: 3.91 (-0.18)
This Growing Concern Accounts For Nearly 500,000 Cancer Cases Each Year
Sean Williams, The Motley Fool - Motley Fool - Sun Dec 07, 12:51PM CST
Source: WIkimedia Commons. When it comes to diagnosed diseases and disorders few, if any, are scarier than cancer. Based on statistics from the Centers for Disease Control and Prevention, cancer is the second-leading cause of death in the United...
ZFGN: 22.56 (+0.08), OREX: 5.74 (-0.02), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Will Diabetes Drugs Enter The Anti-Obesity Space?
Spencer Osborne - at Seeking Alpha - Sun Dec 07, 5:58AM CST
OREX: 5.74 (-0.02), NVO: 44.48 (-1.14), AZN: 71.80 (-1.80), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Belviq Sales About What Was Expected For Thanksgiving Week
Spencer Osborne - at Seeking Alpha - Sun Dec 07, 2:12AM CST
ARNA: 3.91 (-0.18)
Actelion submits MAA for pulmonary hypertension drug
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 2:36PM CST
MSTX: 0.47 (+0.01), GILD: 104.13 (-0.18), UTHR: 129.37 (-1.86), GSK: 42.42 (-0.93), ARNA: 3.91 (-0.18)
Could This Company Follow in Dendreon's Footsteps?
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 03, 10:11AM CST
When it comes to the investing world, the ultimate compliment you or your company can get is being compared to the likes of visionaries like Warren Buffett or iconic companies likes Apple or Coca-Cola . If there's an antithesis to the iconic...
KO: 40.91 (-0.62), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18), AAPL: 109.73 (-1.89)
Why Orexigen Therapeutics, Inc. Stock Rocketed 43% Higher in November
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 03, 7:36AM CST
OREX data by YCharts What: Shares of Orexigen Therapeutics , a biopharmaceutical company focused on developing drugs to treat obesity, put on some serious heft and gained 43% during the month of November, data courtesy of S&P Capital IQ...
OREX: 5.74 (-0.02), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Arena's CEO Presents at Piper Jaffray 26th Annual Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Dec 02, 10:50AM CST
ARNA: 3.91 (-0.18)
Belviq Approaches 10,000 Ads Aired
Spencer Osborne - at Seeking Alpha - Mon Dec 01, 1:42PM CST
VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Belviq Sales Remain Flat, Next Week Will Have A Dip
Spencer Osborne - at Seeking Alpha - Mon Dec 01, 5:32AM CST
ARNA: 3.91 (-0.18)
Arena Pharmaceutical's Belviq Requires Patience And Understanding
Jim Roof - at Seeking Alpha - Fri Nov 28, 12:57PM CST
ARNA: 3.91 (-0.18)
The Anti-Obesity Drugs Market Growing at 39% CAGR to 2019
PR Newswire - Fri Nov 28, 5:30AM CST
ReportsnReports.com adds Global Anti-Obesity Drugs Market 2015-2019 research report of 78 pages to the fast growing pharmaceuticals industry intelligence and data collection of its library. According to this research, the global anti-obesity drugs market is set to grow at a CAGR of 39.45% over the period 2014-2019. Complete research is available at http://www.reportsnreports.com/reports/318547...-2019.html .
ARNA: 3.91 (-0.18)
Arena awarded composition of matter patent for ralinepag
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 10:28AM CST
ARNA: 3.91 (-0.18)
Contrave Sales Continue To Impress
Spencer Osborne - at Seeking Alpha - Fri Dec 12, 3:26PM CST
OREX: 5.74 (-0.02), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Arena: Belviq Sales See Pleasant Rebound
Spencer Osborne - at Seeking Alpha - Fri Dec 12, 3:05PM CST
OREX: 5.74 (-0.02), ARNA: 3.91 (-0.18)
Arena Pharmaceuticals (ARNA) Weak On High Volume Today
at The Street - Fri Dec 12, 9:01AM CST
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate
ARNA: 3.91 (-0.18)
Assessing The Beginnings Of The Orexigen Launch Of Contrave
Spencer Osborne - at Seeking Alpha - Wed Dec 10, 12:09PM CST
OREX: 5.74 (-0.02), ARNA: 3.91 (-0.18)
Belviq Still Lacking Coverage At The Top, But Could Recover In The Exchanges
Clinically Sound Investor - at Seeking Alpha - Tue Dec 09, 7:02AM CST
ARNA: 3.91 (-0.18)
Biotech Weekly: Everything You Want To Know About Small Cap Biotech Cult Stocks
Daniel Ward - at Seeking Alpha - Mon Dec 08, 10:35AM CST
HEB: 0.25 (-0.01), IBIO: 0.69 (unch), MNKD: 5.11 (-0.14), ARNA: 3.91 (-0.18)
Global Anti-Obesity Drugs Market 2015-2019: High Drug Development Costs & Stiff Market Competition
M2 - Mon Dec 08, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/pvmmtv/global) has announced the addition of the "Global Anti-Obesity Drugs Market 2015-2019" report to their offering. The Global Anti-obesity Drugs market to grow at a CAGR of 39.45 percent over the period 2014-2019 Obesity is a medical condition in which there is surplus accumulation of fat in the body. It is linked with increased illness risk, disability, and death. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure. Fierce competition among vendors to manufacture and market drugs that are both effective and safe is one of the major trends in the market. Competition in the market is expected to further intensify with the entry of new drugs in the market during the forecast period. The landscape is vast, with competitors ranging from Arena Pharmaceuticals and Orexigen Therapeutics to big pharmaceutical companies gearing up to make harmless anti-obesity drugs with lesser side effects. According to the report, an increase in the prevalence of obesity is one of the main drivers of the market. The prevalence of obesity is very high worldwide. An increase in the prevalence of obesity offers huge opportunities for drug manufacturing companies to develop and manufacture highly effective drugs. Further, the report states that the high cost of development of drugs is one of the primary challenges faced by the market. Regardless of the numerous benefits, the high cost involved with the development of anti-obesity drugs has direct impact on the pricing of the drug, thereby impeding the acceptability among patients. The Global Anti-obesity Drugs market can be divided into two segments: - Peripherally Acting Anti-obesity Drugs - Centrally Acting Anti-obesity Drugs Key Vendors - Arena Pharmaceuticals - F. Hoffmann-La Roche - GlaxoSmithKline - Orexigen Therapeutics - Vivus Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Types of Obesity - Causes of Obesity - Classification of Obesity - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/pvmmtv/global
OREX: 5.74 (-0.02), GSK: 42.42 (-0.93), ARNA: 3.91 (-0.18)
Arena's Belviq - Regulatory Update And A Recall
Spencer Osborne - at Seeking Alpha - Mon Dec 08, 8:01AM CST
ARNA: 3.91 (-0.18)
This Growing Concern Accounts For Nearly 500,000 Cancer Cases Each Year
Sean Williams, The Motley Fool - Motley Fool - Sun Dec 07, 12:51PM CST
Source: WIkimedia Commons. When it comes to diagnosed diseases and disorders few, if any, are scarier than cancer. Based on statistics from the Centers for Disease Control and Prevention, cancer is the second-leading cause of death in the United...
ZFGN: 22.56 (+0.08), OREX: 5.74 (-0.02), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Will Diabetes Drugs Enter The Anti-Obesity Space?
Spencer Osborne - at Seeking Alpha - Sun Dec 07, 5:58AM CST
OREX: 5.74 (-0.02), NVO: 44.48 (-1.14), AZN: 71.80 (-1.80), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Belviq Sales About What Was Expected For Thanksgiving Week
Spencer Osborne - at Seeking Alpha - Sun Dec 07, 2:12AM CST
ARNA: 3.91 (-0.18)
Actelion submits MAA for pulmonary hypertension drug
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 2:36PM CST
MSTX: 0.47 (+0.01), GILD: 104.13 (-0.18), UTHR: 129.37 (-1.86), GSK: 42.42 (-0.93), ARNA: 3.91 (-0.18)
Could This Company Follow in Dendreon's Footsteps?
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 03, 10:11AM CST
When it comes to the investing world, the ultimate compliment you or your company can get is being compared to the likes of visionaries like Warren Buffett or iconic companies likes Apple or Coca-Cola . If there's an antithesis to the iconic...
KO: 40.91 (-0.62), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18), AAPL: 109.73 (-1.89)
Why Orexigen Therapeutics, Inc. Stock Rocketed 43% Higher in November
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 03, 7:36AM CST
OREX data by YCharts What: Shares of Orexigen Therapeutics , a biopharmaceutical company focused on developing drugs to treat obesity, put on some serious heft and gained 43% during the month of November, data courtesy of S&P Capital IQ...
OREX: 5.74 (-0.02), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Arena's CEO Presents at Piper Jaffray 26th Annual Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Dec 02, 10:50AM CST
ARNA: 3.91 (-0.18)
Belviq Approaches 10,000 Ads Aired
Spencer Osborne - at Seeking Alpha - Mon Dec 01, 1:42PM CST
VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Belviq Sales Remain Flat, Next Week Will Have A Dip
Spencer Osborne - at Seeking Alpha - Mon Dec 01, 5:32AM CST
ARNA: 3.91 (-0.18)
Arena Pharmaceutical's Belviq Requires Patience And Understanding
Jim Roof - at Seeking Alpha - Fri Nov 28, 12:57PM CST
ARNA: 3.91 (-0.18)
The Anti-Obesity Drugs Market Growing at 39% CAGR to 2019
PR Newswire - Fri Nov 28, 5:30AM CST
ReportsnReports.com adds Global Anti-Obesity Drugs Market 2015-2019 research report of 78 pages to the fast growing pharmaceuticals industry intelligence and data collection of its library. According to this research, the global anti-obesity drugs market is set to grow at a CAGR of 39.45% over the period 2014-2019. Complete research is available at http://www.reportsnreports.com/reports/318547...-2019.html .
ARNA: 3.91 (-0.18)
Arena awarded composition of matter patent for ralinepag
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 10:28AM CST
ARNA: 3.91 (-0.18)
